ClinicalTrials.gg
RecruitingNCT07011186Updated Jun 8, 2025

A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

A Phase 1/2 interventional study of TQB3909 Tablets + Azacitidine in Myeloid Malignancy, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-08.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Registered 1 year 1 month after the study started (first participant enrolled Apr 2024, registered May 2025).
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
138
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open, multi-center clinical study designed to evaluate the safety, tolerability and efficacy of TQB3909 tablets in combination with azacitidine in subjects with myeloid malignancies.

02

Conditions studied

  • Myeloid Malignancy
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary and signed , good compliance
  • Age: ≥18 years old (at the time of signing the informed consent); expected survival time greater than 3 months.
  • Diagnosis of one of the following diseases:

    1. Acute Myeloid Leukemia (AML):
    2. Myelodysplastic Syndromes (MDS)
    3. Major organ functions are normal.
    4. Fertile male and female subjects agree to use during the study and for 6 months after the study ends.

Exclusion criteria

Exclusion Criteria:

  • Comorbidities and Medical History:

    1. Diagnosis of or current concomitant within 3 years prior to the first dose;
    2. Presence of multiple factors affecting oral drug intake and/or absorption;
    3. Major surgical procedures or significant traumatic injuries within 28 days prior to the first dose;
    4. History of arterial/venous thrombotic events within 6 months prior to the first dose;
    5. History of psychiatric drug abuse that cannot be discontinued, or psychiatric disorders;
    6. Presence of any severe and/or uncontrolled disease in the subject.
  • Tumor-related Symptoms and Treatment:

    1. Diagnosis of Acute Promyelocytic Leukemia (APL), Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN);
    2. Presence of leukemia central nervous system (CNS) involvement or high suspicion of CNS involvement but unable to confirm;
    3. Subjects with extramedullary disease only in AML;
    4. Presence of life-threatening severe leukemia-related complications;
  • Study Treatment-related:

    1. Received within 4 weeks prior to the first dose, or planned to receive live vaccines during the study period;
    2. Participated in other clinical trials involving anti-tumor drugs within 4 weeks prior to the first dose.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
138 participants (estimated)

Study arms

  • Experimental
    TQB3909 Tablets + Azacitidine

    TQB3909 Tablets administered once-daily. 28 days as a treatment cycle.

    Drug: TQB3909 Tablets + Azacitidine

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AE) and serious adverse events (SAE), abnormal laboratory parameters

    Any adverse medical event that occurred from the time the subject signed the informed consent until 28 days after the last dose/start of the new antitumor therapy (whichever occurs first)

    Time frame: Up to 24 weeks

  2. Complete Remission + Complete Remission with Partial Hematologic Recovery (CR+CRh) Rate

    Complete Remission + Complete Remission with Partial Hematologic Recovery (CR+CRh) Rate

    Time frame: Up to 4 weeks

Secondary outcomes

  1. Acute Myeloid Leukemia: Investigator-Assessed Objective Response Rate (ORR)

    Proportion of subjects with best response as Complete Remission (CR), Complete Remission with Incomplete Hematologic Recovery (CRi), Morphologic Leukemia-Free State (MLFS), or Partial Remission (PR)

    Time frame: Up to 4 weeks

  2. Myelodysplastic Syndromes: Investigator-Assessed Objective Response Rate (ORR)

    Proportion of subjects with best response as CR, Morphological Complete Remission (mCR), or PR

    Time frame: Up to 4 weeks

  3. Acute Myeloid Leukemia: Complete Remission + Complete Remission with Incomplete Hematologic Recovery (CR+CRi) Rate

    Proportion of subjects with best response as CR+CRi. CRi refers to meeting all CR criteria except for residual neutrophil count decrease (ANC \< 1.0 × 109/L) or platelet count decrease (PLT \< 100 × 109/L).

    Time frame: Up to 4 weeks

  4. Acute Myeloid Leukemia: Complete Remission + Complete Remission with Partial Hematologic Recovery (CR+CRh) Rate

    Proportion of subjects with best response as CR

    Time frame: Up to 4 weeks

  5. Acute Myeloid Leukemia and Myelodysplastic Syndromes: Complete Remission (CR) Rate

    Proportion of subjects with best response as CR

    Time frame: Up to 4 weeks

  6. Acute Myeloid Leukemia: Duration of Remission (DOR)

    For all subjects with best response as CR, CRi, MLFS, or PR, the time from the first date of achieving remission to the first recorded date of disease progression, relapse, or death (whichever occurs first).

    Time frame: Up to 4 weeks

  7. Acute Myeloid Leukemia: Duration of CR + CRh (DOCR+CRh)

    For all subjects with best response as CR or CRh, the time from the first date of achieving CR or CRh to the first recorded date of relapse or death (whichever occurs first).

    Time frame: Up to 4 weeks

  8. Acute Myeloid Leukemia: Duration of Complete Remission (DOCR)

    For all subjects with best response as CR, the time from the first date of achieving CR to the first recorded date of relapse or death (whichever occurs first).

    Time frame: Up to 4 weeks

  9. Acute Myeloid Leukemia: Time to First Complete Remission (TTCR)

    For all subjects with best response as CR or CRh, the time from the first date of medication to the first date of CR or CRh.

    Time frame: Up to 4 weeks

  10. Acute Myeloid Leukemia: Time to First Complete Remission (TTCR)

    For subjects with best response as CR, the time from the first date of medication to the first date of CR.

    Time frame: Up to 4 weeks

  11. Acute Myeloid Leukemia and Myelodysplastic Syndromes: Event-Free Survival (EFS)

    Defined as the duration from the first dose of medication to treatment failure, relapse after CR or CRi, or death due to any cause (whichever occurs first). Treatment failure is defined as not achieving CR or CRi at any assessment time during treatment. Subjects with treatment failure will be considered to have an EFS event on the first day after the first dose. For subjects with CR or CRi, the event time will be the time of disease relapse or death (whichever occurs first).

    Time frame: Up to 4 weeks

  12. Acute Myeloid Leukemia and Myelodysplastic Syndromes: Overall Survival (OS)

    The time from the first dose of medication to the date of death due to any cause.

    Time frame: Up to 60 weeks

  13. Myelodysplastic Syndromes: Hematologic Improvement (HI) Rate

    Proportion of subjects meeting Hematologic Improvement (HI) criteria, including Hematologic Improvement - Erythrocyte (HI-E), Hematologic Improvement - Platelet (HI-P), and Hematologic Improvement - Neutrophil (HI-N).

    Time frame: Up to 4 weeks

  14. Myelodysplastic Syndromes: Transfusion Independence Rate

    The proportion of subjects who did not require transfusions for at least 56 days after baseline, relative to the number of baseline transfusion-dependent and transfusion-independent subjects.

    Time frame: Up to 8 weeks

07

Study locations

1 of 21 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Oct 2025, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2025
First posted
Jun 8, 2025
StartActual
Apr 17, 2024
Primary completionEst.
Oct 2025
CompletionEst.
Oct 2026
Last update
Jun 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07011186
Responsible party
Sponsor
First posted
Jun 8, 2025
Start date
Apr 17, 2024
Primary completion
Oct 2025 (estimated)
Completion
Oct 2026 (estimated)
Last update
Jun 8, 2025

Study contacts

JianXiang Wang, Master
Contact
wangjx@ihcams.ac.cn
13821389157

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bcl-2 Inhibitor TQB3909 · Azacitidine

Start the discussion